# Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

> **NCT01865292** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 40 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT01865292
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865292, "Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01865292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*